Catalog #CPB515
Bispecific anti-mouse LAG3 x anti-mouse PD-1 - PREORDER
Clone
Derived from clones C9B7W and RMP1-14
Reactivities
Mouse
Isotype
mouse IgG2a (LALA-PG), κ
Product Description
CPB515 is a 1+1 symmetric bivalent bispecific engineered to simultaneously target mouse programmed cell death protein 1 (PD-1, CD279) and mouse lymphocyte-activation gene 3 (LAG3). CPB515 contains the murine IgG2a constant region to reduce immunogenicity and the formation of anti-drug antibodies (ADAs) in mouse models and LALA-PG Fc-silencing mutations to abolish antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) while minimizing Fc-driven off-target toxicity and depletion of checkpoint‑expressing effector T cells. This bispecific is designed to work by simultaneously blocking two non‑redundant inhibitory pathways on exhausted T cells, thereby more effectively reversing dysfunction than targeting either PD-1 or LAG‑3 alone. PD-1 is an inhibitory receptor on activated and chronically stimulated T cells whose engagement by PD-L1/PD-L2 dampens TCR signaling, reduces cytokine production, and promotes an exhausted phenotype in tumors. LAG-3 is a co‑inhibitory receptor expressed on exhausted CD8 T cells, Tregs, and other lymphocytes, and binding to ligands such as MHC II contributes to reduced proliferation, cytokine secretion, and cytotoxic function especially in chronic antigen exposure and in the tumor microenvironment. PD-1 and LAG-3 are often co‑expressed on highly exhausted, tumor-reactive tumor infiltrating lymphocytes (TILs). Bispecifics that concurrently bind both targets can concentrate functional activity on this subset, enhancing proximal TCR signaling and restoring effector function, effectively reactivating anti-tumor activity while potentially sparing less‑activated peripheral T cells.
Specifications
| Isotype | Mouse IgG2a (LALA-PG), κ |
|---|---|
| Recommended Isotype Control(s) | Bispecific mouse IgG2a (LALA-PG), kappa isotype control |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Mutations | LALA-PG |
| Reported Applications |
ELISA For information on in-vivo applications, please contact technicalservice@bioxcell.com |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from mammalian cell supernatant in an animal-free facility |
| Molecular Weight | 145.3 |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |